94. Primary sclerosing cholangitis
134 clinical trials,   105 drugs   (DrugBank: 37 drugs),   18 drug target genes,   131 drug target pathways

Searched query = "Primary sclerosing cholangitis", "PSC"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
9 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03710122
(ClinicalTrials.gov)
January 23, 202015/10/2018Vancomycin for Primary Sclerosing CholangitisA Prospective, Randomized, Multi-centered, Placebo-controlled Clinical Trial of Oral Vanycomycin in Adults With Primary Sclerosing CholangitisPrimary Sclerosing CholangitisDrug: Vancomycin;Other: PlaceboElizabeth CareyArizona State UniversityRecruiting18 Years75 YearsAll102Phase 2;Phase 3United States;Canada
2NCT03046901
(ClinicalTrials.gov)
December 7, 201631/1/2017Vancomycin Treatment in Recurrent PSC in Liver Transplant PatientsOral Vancomycin Treatment in Recurrent Primary Sclerosing Cholangitis in Liver Transplant RecipientsPrimary Sclerosing Cholangitis;Post- Orthotopic Liver TransplantationDrug: VancomycinOchsner Health SystemNULLWithdrawnN/AN/AAll0N/AUnited States
3NCT02605213
(ClinicalTrials.gov)
September 201531/10/2015Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis PatientsEvaluation of Effectiveness and Safety of Oral Vancomycin in Treatment of Primary Sclerosing Cholangitis.Primary Sclerosing CholangitisDrug: Vancomycin;Drug: PlaceboTehran University of Medical SciencesNULLRecruiting18 Years60 YearsBoth30Phase 4Iran, Islamic Republic of
4NCT02464020
(ClinicalTrials.gov)
July 201529/5/2015A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing CholangitisA Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing CholangitisPrimary Sclerosing Cholangitis;Inflammatory Bowel DiseaseDrug: VancomycinUniversity of MinnesotaNULLCompleted18 Years80 YearsAll8Phase 1United States
5EUCTR2009-018034-11-SE
(EUCTR)
29/04/201321/06/2011Open pilot study of treatment with an antibiotic called vancomycin to children and adolescents with chronic inflammation of the bile ducts, called primary sclerosing cholangitis (PSC)Open pilot study of treatment with vancomycin to children and adolescents with primary sclerosing cholangitis - vanco-psc Primary Sclerosing Cholangitis (PSC) is a progressive disease of the biliary system which might lead to increased risk of cholangiocancer. PSC constitutes a common indication for adult liver transplantation (ltx). In 80% of cases PSC is associated with inflammatory bowel disease (IBD), while 3-5 % of patients with colonic IBD, suffer from the disease. The conservative treatment options are few. There is a relatively high risk of recurrency after ltx.;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]Trade Name: Vancomycin
Product Name: vancomycin
Trade Name: vancomycin
Product Name: Vancomycin
Karolinska InstitutetNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
20Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT01802073
(ClinicalTrials.gov)
January 201221/2/2013Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating EffectsTreatment of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating EffectsPrimary Sclerosing CholangitisDrug: Oral VancomycinStanford UniversityNULLCompleted1 YearN/AAll34Phase 3United States
7NCT02137668
(ClinicalTrials.gov)
July 201012/5/2014Treating Primary Sclerosing Cholangitis and Biliary Atresia With VancomycinThe Human Gastrointestinal Tract Microbiota in the Setting of Treating Primary Sclerosing Cholangitis and Biliary Atresia With VancomycinPrimary Sclerosing Cholangitis;Biliary AtresiaDrug: Oral VancomycinSacramento Pediatric GastroenterologyNULLRecruitingN/A40 YearsBoth200Phase 1United States
8NCT01085760
(ClinicalTrials.gov)
February 201010/3/2010A Pilot Study of Vancomycin or Metronidazole in Patients With Primary Sclerosing CholangitisA Pilot Study of Vancomycin or Metronidazole in Patients With Primary Sclerosing CholangitisPrimary Sclerosing CholangitisDrug: Vancomycin;Drug: MetronidazoleMayo ClinicPSC Partners Seeking a Cure FoundationCompleted18 Years75 YearsAll35Phase 1United States
9NCT01322386
(ClinicalTrials.gov)
May 200710/2/2011Gastrointestinal Microbiota in Primary Sclerosing Cholangitis and Biliary Atresia With VancomycinThe Human Gastrointestinal Tract Microbiota in the Setting of Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin.Primary Sclerosing Cholangitis;Biliary AtresiaDrug: VancomycinStanford UniversityNULLCompleted1 Month20 YearsAll32Phase 1NULL